Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Biocryst Pharmaceuticals

Evaluate

Thumbnail
November 23, 2022

Ash 2022 preview – Novartis has Apellis in its sights

Iptacopan looks as good as Empaveli in PNH, with the added bonus of being oral.

Thumbnail
September 16, 2022

Astrazeneca pulls ahead in haemoglobinuria

Article image
Vantage logo
August 23, 2022

Can Kalvista make HAE after Pharvaris’s misstep?

A clinical hold for Pharvaris raises questions about the group’s approach, and could leave the door open for its acute rival.

Article image
Vantage logo
June 28, 2022

Big pharma’s key third-quarter data

GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.

Article image
Vantage logo
May 19, 2022

ERA 2022 – Chinook’s second bird could also fly

Article image
Vantage logo
May 17, 2021

Apellis crosses the finish line – now to pay it back

Article image
Vantage logo
May 11, 2021

Fortunes diverge for solo drug launchers

A solo drug launch is a testing time for a small company, made even tougher by the pandemic.

Article image
Vantage logo
March 22, 2021

Biocryst joins the push against Soliris

Article image
Vantage logo
March 01, 2021

US FDA approval tracker February 2021

Article image
Vantage logo
February 22, 2021

Biocryst looks to raise the profile of its factor D inhibitor

The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.

Article image
Vantage logo
January 22, 2021

Apellis takes the complement fight to Astrazeneca

The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up